JP2017515909A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515909A5
JP2017515909A5 JP2017512461A JP2017512461A JP2017515909A5 JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5 JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
formulation according
seq
concentration
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017512461A
Other languages
English (en)
Japanese (ja)
Other versions
JP6707528B2 (ja
JP2017515909A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053602 external-priority patent/WO2015173782A1/en
Publication of JP2017515909A publication Critical patent/JP2017515909A/ja
Publication of JP2017515909A5 publication Critical patent/JP2017515909A5/ja
Application granted granted Critical
Publication of JP6707528B2 publication Critical patent/JP6707528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017512461A 2014-05-16 2015-05-15 抗体処方物 Active JP6707528B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461994427P 2014-05-16 2014-05-16
US61/994,427 2014-05-16
US201462093734P 2014-12-18 2014-12-18
US62/093,734 2014-12-18
US201462095181P 2014-12-22 2014-12-22
US62/095,181 2014-12-22
PCT/IB2015/053602 WO2015173782A1 (en) 2014-05-16 2015-05-15 Antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035298A Division JP7277681B2 (ja) 2014-05-16 2020-03-02 抗体処方物

Publications (3)

Publication Number Publication Date
JP2017515909A JP2017515909A (ja) 2017-06-15
JP2017515909A5 true JP2017515909A5 (enExample) 2018-06-28
JP6707528B2 JP6707528B2 (ja) 2020-06-10

Family

ID=53200250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512461A Active JP6707528B2 (ja) 2014-05-16 2015-05-15 抗体処方物
JP2020035298A Active JP7277681B2 (ja) 2014-05-16 2020-03-02 抗体処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020035298A Active JP7277681B2 (ja) 2014-05-16 2020-03-02 抗体処方物

Country Status (16)

Country Link
US (5) US10556009B2 (enExample)
EP (3) EP3143047B8 (enExample)
JP (2) JP6707528B2 (enExample)
KR (2) KR20170005099A (enExample)
CN (1) CN106661111A (enExample)
AU (1) AU2015260758B2 (enExample)
BR (1) BR112016026811A2 (enExample)
CA (1) CA2949212C (enExample)
DK (1) DK3143047T3 (enExample)
ES (1) ES2927990T3 (enExample)
IL (1) IL248802B (enExample)
MX (1) MX381232B (enExample)
MY (1) MY185802A (enExample)
SG (1) SG11201609622PA (enExample)
TW (1) TWI694836B (enExample)
WO (1) WO2015173782A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
IL287947B2 (en) 2014-10-23 2024-08-01 Amgen Inc Viscosity reduction of pharmaceutical preparations
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
SG11201901077RA (en) 2016-08-17 2019-03-28 Compugen Ltd Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
US10093731B2 (en) * 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
BR112019021364A2 (pt) * 2017-04-11 2020-05-05 Kiniksa Phamaceuticals Ltd formulação estável de anticorpo anti-osmr
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
CN111989121B (zh) * 2018-04-16 2024-08-13 默克专利股份有限公司 高浓缩蛋白质制剂的粘度降低
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
CA3134401A1 (en) * 2019-03-29 2020-10-08 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against il-5 and use thereof
EP4003417A2 (en) * 2019-07-29 2022-06-01 Compugen Ltd. Anti-pvrig antibodies formulations and uses thereof
WO2021091706A1 (en) * 2019-11-06 2021-05-14 Novartis Ag Treatment for sjögren's syndrome
CN113546252A (zh) * 2020-04-24 2021-10-26 上海君实生物医药科技股份有限公司 抗pcsk9抗体的药物递送装置
GB202006093D0 (en) 2020-04-24 2020-06-10 King S College London Composition
BR112022021499A2 (pt) 2020-04-24 2023-05-09 King S College London Composição compreendendo um anticorpo ige
WO2021249664A1 (en) * 2020-06-12 2021-12-16 Glaxosmithkline Intellectual Property Management Limited Anti-blys antibody for treating proteinuric kidney disease
CN116997359A (zh) 2020-11-18 2023-11-03 阿斯利康(瑞典)有限公司 类固醇节制
CN116897159A (zh) 2021-03-31 2023-10-17 江苏恒瑞医药股份有限公司 截短的taci多肽及其融合蛋白和用途
WO2022223028A1 (zh) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 抗BLyS抗体、其药物组合物及其用途
CA3220318A1 (en) * 2021-06-17 2022-12-22 Glaxosmithkline Intellectual Property Limited Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc)
US20250326850A1 (en) 2021-07-27 2025-10-23 Astrazeneca Ab Treatment of lupus
CN117999291A (zh) * 2022-05-23 2024-05-07 南京融捷康生物科技有限公司 一种稳定的抗体制剂
WO2024027793A1 (en) * 2022-08-05 2024-02-08 I-Mab Biopharma (Hangzhou) Co., Ltd. Bispecific antibodies targeting ifnar1 and blys
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
CN118255895B (zh) * 2024-04-30 2024-10-29 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 抗BAFF和hIL21双特异性抗体及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
ES2392073T3 (es) * 2001-11-08 2012-12-04 Abbott Biotherapeutics Corp. Formulación farmacéutica líquida estable de anticuerpos IGG
CA2542777C (en) * 2003-10-23 2016-02-02 Chiron Corporation Stabilised compositions
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CA2626082C (en) * 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
JP2013530188A (ja) * 2010-06-18 2013-07-25 ヒューマン ゲノム サイエンシズ，インコーポレイテッド 喘息並びに呼吸器系の他のアレルギー性及び炎症性症状を治療するためのｂリンパ球刺激タンパク質アンタゴニストの使用
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
WO2013012022A1 (ja) * 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
CN104768578A (zh) 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
US9762377B2 (en) 2015-09-29 2017-09-12 Cable Television Laboratories, Inc. Hybrid full duplex communications in a radio frequency cable network

Similar Documents

Publication Publication Date Title
JP2019504032A5 (enExample)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP2015522252A5 (enExample)
JP2015120706A5 (enExample)
JP2020524661A5 (enExample)
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
JP2018521638A5 (enExample)
JP2020518598A5 (enExample)
JP2017500018A5 (enExample)
JP2020518600A5 (enExample)
JP2016529229A5 (enExample)
JP2018108081A5 (enExample)
JP2011528902A5 (enExample)
JP2019510739A5 (enExample)
JP2017113019A5 (enExample)
JP2018535650A5 (enExample)
PE20090769A1 (es) Proteinas de union a antigenos que se unen a par-2
JP2016539096A5 (enExample)
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
JP2018536393A5 (enExample)
JP2016519650A5 (enExample)
RU2016100892A (ru) Антитела против tweakr и их применение
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
RU2018112861A (ru) Стабильные антитела, связывающиеся с несколькими антигенами
TW201014602A (en) Prostaglandin E2 binding proteins and uses thereof